Overview

* Lipocine ( LPCN ) Q3 net loss widens to $3.2 mln, impacted by increased R&D expenses

* Royalty revenue from TLANDO sales was $115,000 in Q3 2025

* Company's cash reserves decreased to $15.1 mln from $21.6 mln at end of 2024

Outlook

* Lipocine expects top-line data for LPCN 1154 in Q2 2026

Result Drivers

* INCREASED R&D EXPENSES - Higher R&D costs primarily due to ongoing LPCN 1154 Phase 3 trial for postpartum depression

* RESEARCH AND DEVELOPMENT EXPENSES - were $2.7 million and $1.6 million, respectively, for the quarters ended September 30, 2025 and 2024

* ROYALTY REVENUE - TLANDO sales contributed $115,000 in royalty revenue during Q3 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.59

Q3 Net -$3.20

Income mln

Q3 Basic -$0.59

EPS

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Lipocine Inc ( LPCN ) is $7.38, about 65.3% above its November 5 closing price of $2.56

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)